Cary Street Partners Investment Advisory’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.5K Buy
173
+52
+43% +$3.55K ﹤0.01% 680
2026
Q1
$7.82K Buy
121
+91
+303% +$6.42K ﹤0.01% 641
2025
Q4
$2.02K Sell
30
-10
-25% -$673 ﹤0.01% 668
2025
Q3
$2.93K Buy
40
+30
+300% +$1.99K ﹤0.01% 580
2025
Q2
$520 Sell
10
-104
-91% -$5.92K ﹤0.01% 589
2025
Q1
$7.28K Buy
114
+14
+14% +$813 ﹤0.01% 498
2024
Q4
$4.78K Sell
100
-120,034
-100% -$6.15M ﹤0.01% 465
2024
Q3
$6.88M Buy
120,134
+99,886
+493% +$5.73M 0.25% 100
2024
Q2
$1.06M Sell
20,248
-90
-0.4% -$3.95K 0.04% 337
2024
Q1
$827K Hold
20,338
0.04% 365
2023
Q4
$752K Hold
20,338
0.04% 357
2023
Q3
$777K Hold
20,338
0.04% 334
2023
Q2
$734K Hold
20,338
0.05% 310
2023
Q1
$777K Buy
20,338
+25
+0.1% +$1.17K 0.06% 276
2022
Q4
$1.16M Buy
20,313
+25
+0.1% +$1.28K 0.09% 217
2022
Q3
$802K Buy
20,288
+70
+0.3% +$3.09K 0.07% 253
2022
Q2
$890K Buy
+20,218
New +$874K 0.08% 223

Other funds holding HALO

Cary Street Partners Investment Advisory's HALO Position: Q2 2026 in Review

Cary Street Partners Investment Advisory increased its Halozyme (HALO) stake by 43% in Q2 2026, buying an estimated $3.55K and bringing the position to 173 shares worth $13.5K. The position accounts for ﹤0.01% of the portfolio, ranked #680.

Cary Street Partners Investment Advisory first reported a position in HALO in Q2 2022 and has held it in 17 quarters since. The position peaked at $6.88M in Q3 2024. 343 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Cary Street Partners Investment Advisory held 173 shares of Halozyme worth $13.5K as of Q2 2026.
  • Cary Street Partners Investment Advisory bought 52 Halozyme shares in Q2 2026, an estimated $3.55K.
  • Halozyme made up ﹤0.01% of Cary Street Partners Investment Advisory's portfolio in Q2 2026, its #680 holding.
  • Cary Street Partners Investment Advisory first reported a position in Halozyme in Q2 2022 and has held it in 17 quarters since.
  • Cary Street Partners Investment Advisory's Halozyme position peaked at $6.88M in Q3 2024.
  • 343 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Cary Street Partners Investment Advisory's 13F filing for Q2 2026, filed 17 Jul 2026.